Subgroup analyses from previous phase 3 studies investigating first-line PD-1 inhibition in patients with ESCC have shown that those with higher PD-L1 expression may derive more favorable outcomes from the addition of PD-1 inhibitors than their counterparts with low or no PD-L1 expression2–4. Here, PDCD1 is linked to esophageal squamous cell carcinoma.